Isis Pharmaceuticals Announces Positive Phase 1 Results with ISIS-APO(a) Rx

Isis Pharmaceuticals (NASDAQ: ISIS ) announced today positive results from a Phase 1 study with ISIS-APO(a)Rx. These data were presented by Dr. Sotirios Tsimikas at the Vascular Biology Working Group global chapter meeting occurring concurrently with the American Heart Association (AHA) in Dallas, Texas. These data will also be